Stockscreener 앱 받기
452.04
1.37%
6.11
시간 외 거래:
452.04
전일 마감가:
$445.93
열려 있는:
$444.81
하루 거래량:
1.62M
Relative Volume:
1.09
시가총액:
$114.69B
수익:
$11.74B
순이익/손실:
$3.68B
주가수익비율:
31.86
EPS:
14.1888
순현금흐름:
$3.34B
1주 성능:
-0.76%
1개월 성능:
+4.11%
6개월 성능:
-1.74%
1년 성능:
-2.60%
1일 변동 폭
$444.81
$456.00
1주일 범위
$433.81
$457.17
52주 변동 폭
$362.50
$519.68
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
MASTERINVEST Kapitalanlage GmbH Purchases Shares of 5,784 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Westwood Holdings Group Inc. - MarketBeat
Lazard Asset Management LLC Has $213.83 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Provident Investment Management Inc. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Position Lifted by Liontrust Investment Partners LLP - MarketBeat
Marex Group plc Invests $2.98 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Coppell Advisory Solutions LLC Buys 2,846 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025? - Yahoo Finance
How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX is Bellevue Group AG's 8th Largest Position - MarketBeat
2 Healthcare Stocks to Buy Ahead of the New Year - The Globe and Mail
Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know - MSN
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Sei Investments Co. Has $132.41 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CIBC Asset Management Inc Sells 4,393 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - Finviz
Alliancebernstein L.P. Has $1.95 Billion Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025) - ts2.tech
United States Orphan Drugs Market to Reach USD 486.51 Billion - openPR.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $515.00 at Wells Fargo & Company - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Investment Management Corp of Ontario - MarketBeat
This Week’s CGT News: Vertex’s Gene Therapies Show Promise in Younger Children - The Medicine Maker
Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $515 From $460, Maintains Overweight Rating - marketscreener.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Jump Financial LLC - MarketBeat
Ossiam Has $2.05 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Diadema Partners LP Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of Nova Scotia Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
State Street Corp Has $5.24 Billion Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by SVB Wealth LLC - MarketBeat
Daiwa Securities Group Inc. Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Axa S.A. Buys 10,477 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Disney, Nu Holdings, Phillips 66 And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Vertex Will Seek Regulatory Approval for Casgevy in Younger Sickle Cell, Beta-Thalassemia Patients - Precision Medicine Online
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Vertex's Gene Therapy Works In Children With Blood Disorders - Benzinga
Thematics Asset Management Acquires 2,642 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - BioSpace
Federated Hermes Inc. Acquires 23,726 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
David And Goliath: How A Parent-Led Buyers’ Club Challenged Cystic Fibrosis Giant Vertex - Citeline News & Insights
VRTX Stock Quote Price and Forecast - CNN
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Marshall Wace LLP Has $52.09 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
California Public Employees Retirement System Has $322.79 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cerity Partners LLC Purchases 10,768 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Arrowstreet Capital Limited Partnership Purchases Shares of 61,470 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? - sharewise.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Chairman Jeffrey Leiden Sells 63,781 Shares - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
0.91%
자본화:
|
볼륨(24시간):